Two Long-Standing Independent IRBs Met Terms to Merge
Independent Review Consulting (IRC) and the Ethical Review Committee (ERC), both Independent Institutional Review Boards (IRB) representing nearly 50 years of combined service to the research industry are pleased to announce the finalization of their merger agreement.
While the individual boards of each company will continue their review of existing projects respectively, all new submissions of business will be accepted and managed by Ethical and Independent Review Services, LLC (E&I). E&I will offer review of research by an AAHRPP accredited board in California. A second board in the Midwest anticipates receipt of accreditation in the coming months.
Services offered through E&I will include reviews of both private and federally funded research, training and consulting services, and the development of more specialized review boards. Both companies are excited by this opportunity to provide a larger spectrum of review services and a greater base of experience from which they can support their human subject protection program.
Both companies have experience in the review of late-stage, multi-center trials. While IRC specializes in medical devices and federally funded studies, ERC has developed processes specializing in efficient turn-around of large, late-stage multi-center trials.
An E&I Review Services website, with automated forms, will be available at completion of merger, anticipated in coming weeks.
Behind the Buzz: Why Clinical Research Leaders Flock to SCOPE Summit
February 7th 2025In this episode, we meet with Micah Lieberman, Executive Conference Director for SCOPE Summit (Summit for Clinical Ops Executives) at Cambridge Innovation Institute. We will dive deep into the critical role of collaboration within the clinical research ecosystem. How do we bring together diverse stakeholders—sponsors, CROs, clinical trial tech innovators, suppliers, patients, sites, advocacy organizations, investors, and non-profits—to share best practices in trial design, program planning, innovation, and clinical operations? We’ll explore why it’s vital for thought leaders to step beyond their own organizations and learn from others, exchanging ideas that drive advancements in clinical research. Additionally, we’ll discuss the pivotal role of scientific conferences like SCOPE Summit in fostering these essential connections and collaborations, helping shape the future of clinical trials. Join us as we uncover how collective wisdom and cross-industry partnerships are transforming the landscape of clinical research.
Reaching Diverse Patient Populations With Personalized Treatment Methods
January 20th 2025Daejin Abidoye, head of solid tumors, oncology development, AbbVie, discusses a number of topics around diversity in clinical research including industry’s greatest challenges in reaching diverse patient populations, personalized treatment methods, recruitment strategies, and more.
